As well as reducing the risk of worsening heart failure and cardiovascular death in patients with heart failure and a broad range of ejection fractions, SGLT2 inhibitors increase haematocrit and haemoglobin, which is thought to be due to either reductions in plasma volume, increased erythropoiesis, or both.3, 4. The gene discussed is SLC5A2; the disease is heart failure.